PTTP

PTTP is a novel, potent, and selective small molecule antagonist of the adenosine A2A receptor (A2AR). It was developed as a potential therapeutic agent for Parkinson's disease (PD) to alleviate motor symptoms. PTTP exhibits high binding affinity (Ki of 6.3 nM) and significant selectivity for the A2A receptor over the A1 receptor (selectivity ratio of 4603). In preclinical studies, PTTP has demonstrated the ability to antagonize cAMP signaling and attenuate motor deficits, such as catalepsy and akinesia, in mouse models of Parkinson's disease without significant neurotoxicity. Its chemical structure is based on a thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold.

Other names

8-(furan-2-yl)-3-phenethylthiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione8-(furan-2-yl)-3-phenethylthiazolo[1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione